
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is financially sound with increasing revenues and a diverse portfolio of ophthalmic pharmaceutical products. Through potential catalysts like new code for IOPIDINE and updated clinical data for IHEEZO, as well as strategic plans for expanding sales of VEVYE, the company shows strong potential for growth in the future. However, they face industry risks that could impact their success, so continued monitoring is necessary.
Bears say
Harrow is facing challenges such as a recovery of lower year-over-year revenue expected in the short term due to the buildup of inventory in 4Q25. Additionally, growing pains within both Iheezo and Vevye, while problematic, represent a high demand for the drugs and a likely long-term solution for cataract surgery. However, changes in the company's business rules may affect new patient starts, and the unexpected $8M hit on Vevye is concerning. While management's reiteration of guidance for 2026 shows a slight increase at the higher end, it is still a bear to base case estimate, indicating a relatively weak financial performance.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares